{"organizations": [], "uuid": "65ed9bdbc0e5b53c63b2698b7a99d71fd5e0a774", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-adocia-announces-positive-topline/brief-adocia-announces-positive-topline-data-from-study-of-biochaperone-idUSFWN1PK1K1", "country": "US", "domain_rank": 408, "title": "BRIEF-Adocia Announces Positive Topline Data From Study Of Biochaperone®", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-25T19:06:00.000+02:00", "replies_count": 0, "uuid": "65ed9bdbc0e5b53c63b2698b7a99d71fd5e0a774"}, "author": "", "url": "https://www.reuters.com/article/brief-adocia-announces-positive-topline/brief-adocia-announces-positive-topline-data-from-study-of-biochaperone-idUSFWN1PK1K1", "ord_in_thread": 0, "title": "BRIEF-Adocia Announces Positive Topline Data From Study Of Biochaperone®", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-adocia announces positive topline data fro", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 25, 2018 / 5:07 PM / Updated 10 minutes ago BRIEF-Adocia Announces Positive Topline Data From Study Of Biochaperone® Reuters Staff 1 Min Read \nJan 25 (Reuters) - Adocia Sa: \n* ADOCIA ANNOUNCES POSITIVE TOPLINE DATA FROM A DOSE-PROPORTIONALITY STUDY OF BIOCHAPERONE® COMBO IN PEOPLE WITH TYPE 2 DIABETES \n* ADOCIA SA - STUDY CONFIRMED PREVIOUS RESULTS THAT BIOCHAPERONE COMBO ACTS SIGNIFICANTLY FASTER AND LASTS SIGNIFICANTLY LONGER THAN HUMALOGMIX * ADOCIA SA - ‍ALL TREATMENTS WERE WELL TOLERATED​ \n* ADOCIA SA - BOTH PRIMARY ENDPOINTS WERE MET IN STUDY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-25T19:06:00.000+02:00", "crawled": "2018-01-25T19:23:40.004+02:00", "highlightTitle": ""}